Physician profile
Rikin Patel
NPI 1629360326
$5,230.01
in general payments reported to CMS, 2019-2025
30 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $340 · 2021: $467 · 2022: $373 · 2023: $601 · 2024: $1,484 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,588.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $958.55 | 2019-2024 | Xarelto |
| Inari Medical, INC. | $490.14 | 2023-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $482.64 | 2019-2025 | |
| Medtronic, INC. | $432.40 | 2021-2025 | Corevalve Evolut R, Linq II, Emprint |
| Stryker Corporation | $410.62 | 2025 | Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $263.76 | 2019-2025 | Repatha, Repatha |
| Abiomed | $250.29 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $192.48 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.63 | 2021-2025 | Jardiance |
| Pfizer INC. | $161.75 | 2023-2025 | |
| Amarin Pharma, INC. | $147.08 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $131.33 | 2024 | |
| Bolton Medical INC | $128.99 | 2024 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Astrazeneca Pharmaceuticals LP | $125.67 | 2019-2025 | Farxiga, Lokelma |
| Edwards Lifesciences Corporation | $121.80 | 2019-2025 | Sapien 3 Ultra Resilia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $106.20 | 2023-2024 | Verquvo |
| Boston Scientific Corporation | $102.33 | 2022-2025 | General - Embolics, Embold Fibered, Icefx Cryoablation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.46 | 2021-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $91.77 | 2022-2025 | Eliquis |
| Medtronic Vascular, INC. | $68.58 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $49.02 | 2022-2025 | |
| Abbott Laboratories | $46.38 | 2025 | Dragonfly Opstar, Pressurewire |
| Novo Nordisk INC | $37.06 | 2024-2025 | Rybelsus, Ozempic |
| Teleflex LLC | $33.25 | 2024-2025 | Supercross, Turnpike |
| Chiesi USA, INC. | $30.61 | 2020-2021 | |
| Roche Diagnostics Corporation | $27.43 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.58 | 2024 | Optimizer |
| Bard Access Systems, INC. | $14.04 | 2019 | |
| Tactile Systems Technology INC | $11.00 | 2019 | |
| Cardiovascular Systems INC. | $9.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rikin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.